

CORRECTION

Open Access



Correction: 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes

Amélio F. Godoy-Matos^{1,2}, Cynthia Melissa Valério^{1,2}, Wellington S. Silva Júnior^{1,3*}, João Marcello de Araujo-Neto^{1,4} and Marcello Casaccia Bertoluci^{1,5}

Correction: *Diabetology & Metabolic Syndrome* (2024) 16:23
<https://doi.org/10.1186/s13098-024-01259-2>

The colour of the recommendation 8 should be changed from green to orange and the number to be changed from 1 to 11b. The original article [1] has been corrected.

The original article can be found online at <https://doi.org/10.1186/s13098-024-01259-2>.

*Correspondence:

Wellington S. Silva Júnior
wellington.santana@ufma.br

¹ Sociedade Brasileira de Diabetes (SBD), São Paulo, Brazil

² Instituto Estadual de Diabetes e Endocrinologia do Rio de Janeiro (IEDE), Rio de Janeiro, RJ, Brazil

³ Endocrinology Discipline, Department of Medicine I, Faculty of Medicine, Center of Biological Sciences, Universidade Federal do Maranhão (UFMA), Praça Gonçalves Dias, 21, Centro, São Luís, MA CEP 65020-240, Brazil

⁴ Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil

⁵ Universidade Federal do Rio Grande Do Sul (UFRGS), Porto Alegre, RS, Brazil

Changed from

R8. Combination of antidiabetic agents with proven benefits on MASLD MAY BE CONSIDERED in the treatment steatohepatitis and/or fibrosis in people with type 2 diabetes.

I **C**

to

R8. Combination of antidiabetic agents with proven benefits on MASLD MAY BE CONSIDERED in the treatment steatohepatitis and/or fibrosis in people with type 2 diabetes.

11b **C**

Published online: 28 February 2024



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reference

1. Godoy-Matos AF, Valério CM, Silva Júnior WS, de Araujo-Neto JM, Bertoluci MC. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes. *Diabetol Metab Syndr.* 2024;16:23. <https://doi.org/10.1186/s13098-024-01259-2>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.